Tissium, a Paris, France and Boston, MA-based medtech company developing biomorphic programmable polymers for tissue reconstruction, raised $50M in Series D funding.
The round saw participation from Fonds Stratégique des Transitions, managed by ISALT, Merieux Developpement and returning Cathay Health, Credit Mutuel Innovation and Sofinnova Partners.
The company intends to use the funds to finance its commercial launch and platform extension. The financing will allow Tissium to continue to execute on its development plan, funding the company for the commercialisation of its first products in nerve and hernia repair and fueling the extension of its pipeline of products and its platform.
Led by CEO Christophe Bancel, Tissium is a MedTech company dedicated to the development and commercialization of products derived from its proprietary family of fully biosynthetic, biomorphic, and programmable polymers to address multiple unmet clinical needs, including atraumatic tissue repair and reconstruction.
Currently, the company has a pipeline of seven products across three verticals, including sutureless nerve repair, hernia repair and cardiovascular sealants. Each product is designed to enhance the tissue reconstruction process. In addition, Tissium develops complementary delivery and activation devices for enhanced performance and usability of its products.
The company’s technology is based on research and intellectual property from the laboratories of Professor Robert Langer (MIT) and Professor Jeffrey M. Karp (Brigham and Women’s Hospital), who cofounded Tissium in 2013.